Phase I Study of BC008-1A Injection in Patients With Advanced Solid Tumors
Conditions
- Advanced Esophageal Cancers
- Advanced Non-small Cell Lung Cancer (NSCLC)
Interventions
- BIOLOGICAL: BC008-1A 900mg
- BIOLOGICAL: BC008-1A 1200mg
Sponsor
Sichuan Luzhou Buchang Biopharmaceutical Co., Ltd.
Collaborators